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LTRiption factor for the development and function of CD4+ regulatory T-cells (Tregs).
The role of Tregs in HIV-1 infection remains unclear. Here, we show that expression of FOXP3 in primary
human CD4 T-cells signiﬁcantly inhibits HIV-1 infection. Since FOXP3 inhibits NFAT activity, and NFAT
proteins contribute to HIV-1 transcription, we explore a transcriptional repressive function of HIV-1 LTR by
FOXP3. Over-expression of FOXP3 in primary CD4 T-cells inhibits wild-type HIV-1 LTR reporter activity, and
truncation mutants demonstrate that repression of the LTR by FOXP3 requires the dual proximal NFκB/NFAT
binding sites. Interestingly, FOXP3 decreases binding of NFAT2 to the HIV-1 LTR in vivo. Furthermore, FOXP3
does not inhibit infection of HIV-1 NL4-3 which is mutated to disrupt transcription factor binding at either
proximal NFAT or NFκB binding sites. These data suggest that resistance of Tregs to HIV-1 infection is due to
inhibition of HIV-1 LTR transcription by FOXP3.
© 2008 Elsevier Inc. All rights reserved.Introduction
The transcription factor, FOXP3, is highly expressed in CD4+CD25hi
T-cells and is necessary for the development and function of regulatory
T-cells (Tregs) (Fontenot, Gavin, and Rudensky, 2003; Hori, Nomura,
and Sakaguchi, 2003; Khattri et al., 2003). FOXP3 has been shown to
transactivate or to repress target genes (Zheng et al., 2007), and
inhibits both NFAT- and NFκB-mediated transcriptional activation
(Bettelli, Dastrange, and Oukka, 2005). FOXP3 inhibits transcriptional
activation by interaction with forkhead binding sites located immedi-
ately adjacent to the cis-acting NFAT binding sites found in various
cytokine promoters, including IL-2 (Marson et al., 2007; Wu et al.,
2006). FOXP3 may also mediate transcriptional repression indirectly,
without direct binding to DNA. Bettelli et al. showed that FOXP3
directly binds toNFATandNFκB proteins and prevents the activation of, The Children's Hospital of
venue South, Birmingham, AL
ildren's Hospital of Alabama,
ally to this study.
l rights reserved.a number of cytokine genes (Bettelli, Dastrange, and Oukka, 2005).
Thus, there appear to be multiple mechanisms by which FOXP3
inhibits NFAT-responsive gene expression.
HIV/AIDS is characterized by the depletion of CD4 T-cells and
progressive immune dysfunction, including HIV-1 speciﬁc T-cell
responses. Recent studies suggest that Tregs play a major role in
immune suppression. It has been postulated that Tregs are beneﬁcial
for HIV-1 infected individuals because detrimental immune activation
may be controlled by Tregs (Sempere, Soriano, and Benito, 2007). In
contrast, Kinter et al. showed that the HIV-1 speciﬁc CTL response is
suppressed by Tregs and that this suppression continues throughout
the course of HIV disease (Kinter et al., 2007a; Kinter et al., 2007b).
Thus, Treg activity could impact the ability of HIV-1 infected
individuals to control HIV-1 replication.
We show here that over-expression of FOXP3 inhibits HIV-1
infection of human primary CD4 T-cells, inhibiting infection of both
FOXP3+ and FOXP3− cells. We further show that FOXP3 inhibits HIV-1
LTR activity and this transcriptional repression of the HIV-1 LTR
requires the presence of the dual proximal NFκB/NFAT binding sites.
Interestingly, FOXP3 expression decreases the binding of NFAT2 to the
HIV-1 LTR. Based on these data, we hypothesize that FOXP3 makes
CD4+ regulatory T-cells relatively resistant to HIV-1 infection via
transcriptional inhibition of the LTR. Understanding the role of FOXP3
162 N. Selliah et al. / Virology 381 (2008) 161–167and Tregs in HIV-1 infection may lead to new therapeutic approaches
to combat HIV-1 disease and has implications for the potential use of
Treg therapy during HIV-1 infection.
Results and discussion
Lentiviral-mediated expression of FOXP3 in human primary CD4 T-cells
Human primary CD4 T-cells were activated with anti-CD3/CD28
beads and transduced with lentivirus expressing human FOXP3 or
control (as described in the Materials and methods). The level of
expression of FOXP3 protein in transduced cells was determined by
Western blot analysis. As shown in Fig. 1A, FOXP3-transduced cells
expressed 3- to 4-fold more FOXP3 protein than the control-
transduced cells. Surprisingly, in some experiments signiﬁcant levels
of FOXP3 protein were noted in the control GFP-transduced cells. It is
possible that the FOXP3 expression in control cells was due either to
proliferation of a Treg population, or to prolonged expression of
FOXP3 in recently activated T-cells, in response to exogenous IL-2
(Allan et al., 2007; Burchill et al., 2007; Murawski et al., 2006; Zorn
et al., 2006). Nevertheless, the FOXP3-transduced cells expressed
signiﬁcantly more FOXP3 than the control cells (Fig. 1A).
Next, the FOXP3-transduced CD4 T-cells were tested for the ability
to suppress IL-2 production [a well established function of FOXP3,
(Bettelli, Dastrange, and Oukka, 2005)]. Lentiviral-transduced cells
were activated againwith PMA and ionomycin for 6 h and analyzed for
intracellular IL-2. As expected, FOXP3 over-expression markedlyFig. 1. Lentiviral transduction of T-cells. FOXP3 or control GFP lentiviral vectors were
transduced as described in the Material and methods. Lentiviral-transduction efﬁciency
was between 50–85% measured by GFP expression (data not shown). More FOXP3
protein is expressed in transduced cells. (A) Western blotting was done to determine
FOXP3 expression in FOXP3 lentiviral-transduced and control-transduced primary
human CD4 T-cells. The blot shown is from one representative experiment of 3. The
graph to the right depicts ratios of FOXP3 to actin (control) optical density
measurements for control and FOXP3 transduced CD4 T-cells. The data shown are
means±SEM from 3 experiments (⁎p=0.002). These data show that FOXP3-transduced
cells have substantially more FOXP3 protein, relative to actin controls, than control cells.
(B) Intracellular staining of IL-2 in polyclonally activated (6 h) control- (left) or FOXP3-
(right) transduced CD4 T-cells. GFP expression (marking transduced cells) is depicted on
the x-axis and IL-2 expression is portrayed on the y-axis. GFP+ FOXP3-transduced cells
produced notably less IL-2 than GFP+ control cells. One representative of 3 experiments
is shown.suppressed IL-2 production compared to control cells (Fig. 1B). In
this brief assay, the non-transduced (GFP−) cells did not lose IL-2
production, arguing that FOXP3was responsible for the decreased IL-2
production in the GFP+ cells (Fig. 1B). Taken together, these data
suggest that the lentiviral-transduced cells express functional FOXP3
protein and can be used to study the role of FOXP3 in HIV-1 infection
of primary CD4 T-cells.
FOXP3 inhibits HIV-1 infection
Presently, the role of FOXP3-expressing Tregs during HIV-1
infection remains unclear. We investigated the effect of FOXP3
expression in an in vitro model of HIV-1 infection of primary CD4 T-
cells. FOXP3- or control GFP-transduced cells were infected in vitro
with the HIV-1 X4viruses, NL4-3, or IIIB strains, and monitored for
infection by assessing p24-gag expression by using ﬂow cytometry
and ELISA. Transduction of FOXP3 inhibited HIV-1 infection (Fig. 2);
time course analyses showed that FOXP3 inhibited HIV-1 production
at all time points tested post-infection (Figs. 2C and 2D). Interestingly,
further analysis of FOXP3-transduced cell cultures showed that the
GFP− (FOXP3−) population of cells also had fewer p24-gag+ cells
(Fig. 2A, left upper quadrant). In comparison to control-transduced
cells, in FOXP3 transduced cells, NL4-3 p24 expression is reduced by
64%, and for the GFP− cells in the same culture, p24 expression is
reduced by 49%. Similarly, for the IIIB virus, GFP+ (FOXP3+) cells had
a 78% reduction in p24 expression, whereas GFP− cells in the same
culture had a 54% reduction. Thus, the direct inhibitory effect in the
FOXP3+ cells appears to be more substantial than the effect on
neighboring FOXP3− cells. These comparisons are valid in that
roughly equal percentages of cells were transduced with control
versus FOXP3-expressing viruses (∼50% for each virus). These data
suggest that FOXP3+ cells could have suppressive effects on
bystander (FOXP3−) cells within the same culture. Further experi-
ments are needed to assess the trans-suppressive function of Tregs
during HIV-1 infection. For example, is this phenomenon cell contact
dependent? Our preliminary data reveal no change in CXCR4
expression arguing against a viral entry issue. Nevertheless, collec-
tively, these data suggest that FOXP3 inhibits HIV-1 infection and viral
particle production.
In contrast, there are at least three published manuscripts
reporting that FOXP3 increases or augments HIV-1 infection (Antons
et al., 2008; Holmes et al., 2007; Oswald-Richter et al., 2004). Why
such dichotomous results exist remains unclear but there are
differences in the experimental design of these studies. Speciﬁcally,
Oswald-Richter et al. utilized a VSV-G pseudotyped CCR5-tropic (R5)
GFP virus (nef gene deleted) in their experiments (Oswald-Richter
et al., 2004). The authors did not report on the effect of FOXP3 on an
HIV-1 X4 virus in natural Tregs or FOXP3-transduced cells. Although
we have not analyzed natural Tregs directly, our data with VSV-G
pseudotyped R5-Luc (luciferase) virus (nef gene deleted) show that
FOXP3 similarly increases HIV-1 infection by 38.5±5.7% (mean±SEM
of 4 experiments). Thus, it is possible that X4 and R5 viruses respond
differently to FOXP3. Interestingly, a second published report also
utilized an X4 reporter-virus (NL4-Luc, nef gene deleted) in their
experiments and showed that FOXP3 increased HIV-1 infection
(Holmes et al., 2007). Both of these reporter viruses are deleted in
the nef gene, so, theoretically, the Nef protein could play an important
role in the inhibition of HIV-1 infection by FOXP3. However, our initial
experiments show that FOXP3 also inhibits an HIV-1 NL4-3 virus
deleted in the nef gene (data not shown). Another possible difference
explaining the discrepant results is the VSV-G envelope used with the
NL4-3 virus, although our data show that FOXP3 still inhibits VSV-G
pseudotyped wild-type NL4-3 T-cell infection (data not shown). Thus,
the type of virus cannot fully explain the disparate results.
Alternatively, rather than due to the virus, the differences between
our data and previously published reports may have been due to
Fig. 2. FOXP3 expression inhibits HIV-1 infection in T-cells. (A) Primary human CD4 T-cells were activatedwith anti-CD3/CD28 antibody conjugated beads and transducedwith FOXP3
or control lentivirus as described in the Material and methods. Transduced T-cells were infected with HIV-1 NL4-3 or IIIB and monitored for p24-gag expression by ﬂow cytometry.
Lentivirus-transduced cells were monitored by their expression of GFP. Dot plot analysis of one representative experiment of 3 is shown. GFP expression (transduced cells) is noted
along the x-axis, and p24-gag expression is depicted on the y-axis. The percentages of cells for each quadrant are noted in the corners of the respective quadrants. (B) The percentages
of p24+ cells in transduced (control or FOXP3) T-cell cultures are shown in the bar graphs for the NL4-3 and IIIB infected cells, respectively. The mean±SEM of 3 experiments
performed is shown and compared between control and FOXP3-transduced cells (p=0.015 for NL4-3, and p=0.06 for IIIB). (C) The time course of HIV-1 IIIB infection of the control-
and FOXP3-transduced CD4 T-cells is shown as % p24+ cells (y-axis) versus days of infection (x-axis). One representative of 3 experiments is shown. (D) p24 levels (y-axis) in the
supernatant of the IIIB infected CD4 T-cells were measured by ELISA and is shown over time in days post-infection (x-axis). One representative of 3 experiments is presented.
163N. Selliah et al. / Virology 381 (2008) 161–167differences in themethod of T-cell activation and expansion. In both of
the previously published manuscripts, T-cells were activated with
anti-mouse IgG coated plates and soluble anti-CD3 and anti-CD28
antibodies. It is likely that the T-cells were more completely activated
by the anti-CD3/CD28 coated beads used in our experiments (Levine
et al., 1998). In addition, we added 100 U/ml of IL-2 to expand the T-
cells and tomaintain their viability. It is possible, for example, that our
activation protocol maintained FOXP3 expression in the transduced
cells for a longer period of time. In sum, while our data using intact
HIV-1 virions demonstrate that over-expression of FOXP3 inhibits
HIV-1 infection, the mechanism remains unclear.
FOXP3 inhibits HIV-1 LTR transcriptional activity
FOXP3 is a well-known transcriptional repressor of many of its
target genes (Marson et al., 2007). In particular, FOXP3 has been
proposed to inhibit both NFAT and NFκB transcriptional activity
(Bettelli, Dastrange, and Oukka, 2005). Interestingly, the HIV-1 LTR
possesses dual proximal NFAT/NFκB binding sites, which are critical to
optimal transcriptional activity of the promoter (Cron, 2001; Gifﬁn
et al., 2003; Robichaud et al., 2002; Romanchikova et al., 2003). In
order to explore a potential transcriptional repressive function of the
HIV-1 LTR by FOXP3, unstimulated primary human CD4 T-cells were
transfected with an HIV-1 LTR-driven luciferase reporter construct,
with or without co-transfection of a wild-type FOXP3 mammalian
expression vector. The CD4 T-cells were activated with PMA and
ionomycin for 6 h and luciferase activity was determined byluminometry as described in the Materials and methods. Expression
of FOXP3 signiﬁcantly inhibited intact HIV-1 LTR transcriptional
activity (Fig. 3). Truncation of the distal LTR up to −122 bp upstream
of the transcriptional start site still revealed substantial inhibition by
FOXP3 (Fig. 3), but transcriptional inhibition was lost with further
deletion up to −97 bp. Comparing the HIV-1 LTR sequences between
−122 and −97 with published consensus sequences for FOXP3 binding
did not reveal a good match or theoretical binding site for FOXP3
within this stretch of nucleotides. Interestingly, deletion up to −97 bp
disrupts the tandem proximal NFAT/NFκB binding sites, suggesting
that FOXP3-mediated transcriptional inhibition of the HIV-1 LTR
occurs via NFAT and/or NFκB pathways. With each truncation of the
LTR, the transcriptional activity is reduced. However, even the −97
construct still has notable inducible activity (∼400,000 arbitrary light
units) above background (Fig. 3, bottom). In summary, our data show
that FOXP3 over-expression inhibits HIV-1 LTR transcriptional activity
in primary CD4 T-cells and this inhibition requires the presence of
the dual proximal NFAT/NFκB binding sites (Fig. 3).
FOXP3 decreases the binding of NFAT2 to the HIV-1 LTR
To understand the mechanism of FOXP3-mediated inhibition of
HIV-1 infection, we ﬁrst determined whether FOXP3 binds along with
NFAT2 to the HIV-1 LTR, as shown for the IL-2 promoter (Wu et al.,
2006). For strength of manipulation, 293T cells were co-transfected
with control or wild-type FOXP3 expression vector, an NFAT2
expression vector, and an HIV-1 LTR-luciferase reporter plasmid.
Fig. 3. FOXP3 inhibits HIV-1 LTR activity. Primary CD4 T-cells were co-transfected with a FOXP3 (or control) expression vector, one of two different 5′ truncation deletions of HIV-1
LTR-responsive ﬁreﬂy-luciferase reporter genes, and a transfection efﬁciency control Renilla-luciferase construct. T-cells were activated with PMA and ionomycin for 6 h and
corrected luciferase reporter gene activity was measured as a surrogate of HIV-1 LTR transcription rate. Data are represented as percent inhibition of LTR activity by FOXP3 compared
to the pcDNA expression control vector. Comparisons of LTR activity between the −122/+66 and −97/+66 reporter constructs were made using the Student's t-test. Data depicted are
the mean±SEM of 3 experiments performed (p=0.05). Graphs on the bottom represent LTR-luciferase activity for the different deletion constructs as indicated, with and without co-
expression of FOXP3. One representative of 3 experiments is shown.With each truncation of the LTR, the transcriptional activity is reduced. However, even the −97/+66 construct still
has notable inducible activity (∼400,000 arbitrary light units) above background luminometry values (∼1000 ALU, data not shown).
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luciferase assays were performed. The luciferase transcriptional
assay shows that FOXP3 inhibits LTR activity in 293T cells similar
to primary CD4+ T-cells (Fig 4A). However, FOXP3 binding to HIV-1
LTR by ChIP was not detected (Fig. 4B). Interestingly, FOXP3
expression signiﬁcantly decreases NFAT2 binding to the HIV-1 LTR
(Fig. 4B). Our data show a different mechanism for FOXP3-mediated
inhibition of transcription than that reported for IL-2 (Wu et al.,
2006). Nevertheless, Bettelli et al. showed that FOXP3 could bind to
and functionally inhibit NFAT2 and NFκB (Bettelli, Dastrange, and
Oukka, 2005). Therefore, it is possible that FOXP3 binds to NFAT2
and thus blocks the subsequent binding of NFAT2 to the HIV-1 LTR,
required for optimal activation-dependent transcription of HIV-1 in
primary CD4 T-cells. Alternatively, FOXP3 is known to inhibit
induction of NFAT2 in T-cells (Fontenot et al., 2005; Marson et al.,
2007), so that less NFAT2 might be available to bind the LTR.
Whatever the mechanism turns out to be, NFAT2 engagement of the
LTR is decreased in the presence of FOXP3. Along these lines, our
preliminary data suggest FOXP3 over-expression disrupts NFAT2
engagement of the HIV-1 LTR in vivo following activation of virally
infected primary human CD4 T-cells (data not shown).
Based on the in vivo binding studies (Fig. 4B) and our mapping
studies (Fig. 3), it is likely that FOXP3 disrupts NFAT binding at the
dual proximal NFAT/NFκB binding sites (Cron et al., 2000). However,
it is formally possible, yet unlikely, that FOXP3 inhibits LTR activity
via disruption of NFAT binding in the upstream negative regulatory
element (Gaynor, 1992), or in the NFAT binding site in the 5′
untranslated region (Romanchikova et al., 2003). To directly address
the role of the dual proximal NFAT/NFκB sites in FOXP3-mediatied
inhibition of LTR transcription, the effect of mutations in the
proximal NFAT sites on the ability of FOXP3 to inhibit HIV-1 expres-
sion was studied.
Speciﬁcally, the importance of NFAT and/or NFκB binding to the
proximal LTR during FOXP3-mediated inhibition of HIV-1 infection
was tested. NL4-3 viruses mutagenized to disrupt binding of tran-
scription factors to the dual proximal NFAT or NFκB binding sites were
analyzed. FOXP3− or control GFP-transduced cells were infected invitro with NL4-3 wild-type, dual NFAT-mutant, or dual NFκB-mutant
HIV-1 viruses and monitored for infection by assessing p24-gag
expression. Interestingly, FOXP3 did not substantially inhibit produc-
tive infection by themutant HIV-1 viruses, with remarkable reversal of
inhibition seen particularly with the NFAT-mutant virus (Fig. 4C).
Neither the NFAT or NFκB-mutant viruses are inactive but their
expression is reduced (Fig. 4C), consistent with our proposed
mechanism of how FOXP3 inhibits viral replication. Similarly, others
have shown thatmutations in this region of the LTR leading to reduced
binding of NFAT or NFκB can be found in different HIV clades. These
viruses have reduced but not absent transcription in response to T-cell
activation (Lemieux et al., 2004). In addition, we and others have
previously shown that speciﬁc mutations used to generate the viruses
in Fig. 4C lead to speciﬁc inhibition of binding of NFAT or NFκB factors
to the proximal HIV-1 LTR (Cron et al., 2000; Kinoshita et al., 1997).
Collectively, these data suggest that FOXP3mediates inhibition of HIV-
1 infection primarily via interference with NFAT and/or NFκB
transcriptional activation of the proximal HIV-1 LTR.
Taken together, our studies suggest that FOXP3-expressing Tregs
may be relatively resistant to HIV-1 infection. Moreover, FOXP3-
expressing T-cells may also inhibit HIV-1 infection of neighboring CD4
T-cells (Fig. 2A). We speculate that FOXP3 suppresses HIV-1 tran-
scription and could, thereby, convert these cells to latent infection.
Currently, standard latency protocols are performed on resting T-cells
after positive selection of CD4+CD25− T-cells fromHIV+ individuals. It
is possible that by removing CD25+ cells, potential Tregs (FOXP3+
cells) are also removed; this could result in an underestimation of the
number of HIV-1 latently infected T-cells in patients. In addition,
recent publications suggest that Tregs in HIV-1+ individuals suppress
HIV-1 speciﬁc CTLs (Kinter et al., 2007a; Kinter et al., 2007b; Sempere,
Soriano, and Benito, 2007), further confounding the beneﬁt or lack
thereof of Tregs during HIV-1 infection. Immune control of viral
replication represents a balance between the cell-mediated immune
response and the Treg-mediated counter-regulation of such res-
ponses. Given the complexity of Treg biology in HIV-1 disease, treat-
ment of HIV-1 disease with Tregs may be more complicated than the
proposed use of Tregs in cancer or autoimmunity.
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Isolation of CD4 T-cells
CD4 T-cells were isolated by negative selection (RosetteSep;
StemCell Technologies, Vancouver, British Columbia) from hepar-
inized venous blood of healthy adult human donors as described
(Hamilton et al., 2003; Selliah and Finkel, 2001). Isolated cells were
90–95% CD3+CD4+ as detected by ﬂow cytometry.Fig. 4. FOXP3 inhibits HIV-1 infection by interfering with NFAT and/or NFκB function on the
with a control or wild-type FOXP3 expression vector, an NFAT2 expression vector, and an HIV
that FOXP3 inhibits NFAT2 induced LTR activity in 293T cells. One representative of 3 experim
NFAT2 and anti-FOXP3 antibodies was performed using control (without FOXP3) and FOXP3
NFAT2 and FOXP3 engagement in vivo of the HIV-1 LTR reporter sequence was analyzed usin
the Materials and methods. ChIP analysis data are presented as fold differences (mean±S
(⁎p=0.053, compared to NFAT2 without FOXP3). (C) FOXP3 does not substantially inhibit prod
FOXP3 or control lentivirus transduced T-cells were infected with NL4-3 wild-type, NFAT-m
wild-type and NFAT and NFκB-mutant sequences are depicted above the bar graphs with the
represented as % inhibition of infection in FOXP3 transduced cells compared to control c
experiments (⁎⁎p=0.005; ⁎p=0.024). Data shown on the right is a representative example of
the control and FOXP3 transduced cells. The binding mutant viruses have reduced but not aLentiviral transduction and HIV-1 infection
CD4 T-cells were activated with anti-CD3/CD28 coated beads
[Torcylated Dynal beads (Invitrogen, Carlsbad, CA) were conjugated
with anti-CD3 mAb (OKT3, Ortho Biotech Products, L.P., Bridgewater,
NJ) and anti-CD28 mAb (clone 9.3, Ortho Biotech), as per the
manufacturer's recommendations] for 24 h in RPMI containing 10%
human serum (Gemini Bio-Products, Sacramento, CA), penicillin/
streptomycin,L-glutamine and IL-2 (100 U/ml, NIH AIDS Research andHIV-1 LTR. (A) FOXP3 inhibits LTR activity in 293T cells. 293T cells were co-transfected
-1 LTR-luciferase reporter plasmid as described in the Material and methods. Data show
ents is presented. (B) FOXP3 decreases the binding of NFAT2 to the LTR. ChIP with anti-
transfected 293T cells, which were co-transfected with an HIV-1 LTR reporter plasmid.
g PCR ampliﬁcation primers speciﬁc to the proximal HIV-1 LTR sequence as described in
EM) between speciﬁc antibody and isotype control from 3 independent experiments
uctive infection by NL4-3 viruses mutated at either the dual NFATor NFκB binding sites.
utant, or NFκB-mutant HIV-1 viruses and were monitored for p24-gag expression. The
mutant sequences underlined and rendered in bold. Data in the bar graph to the left are
ells for the wild-type and each binding mutant virus. Data are the mean±SEM of 3
1 of 3 experiments. Data are presented as % GFP+, p24+cells for each virus and for both
bsent HIV-1 production in response to T-cell activation.
166 N. Selliah et al. / Virology 381 (2008) 161–167Reference Reagent Program, Bethesda, MD). T-cells were transduced
with lentivirus expressing human FOXP3 co-expressed with GFP, or
control GFP alone, in the presence of Polybrene (8 μg/ml, Sigma, St.
Louis, MO) at TU=40 and cultured at 5×105 cells/ml (Humeau et al.,
2004). Transduced T-cells were washed after 3 days and cultured for
another 2 days. Beads were removed using a magnet (Invitrogen), and
T-cells were infected with HIV-1 NL4-3 or IIIB strains (2 μg of p24-gag
by ELISA per 1×106 cells, with 20 μg/ml DEAE-dextran) and cultured
with IL-2 (100 U/ml) for 3 days (Rapaport et al., 1998; Selliah et al.,
2006). Infection of T-cells was monitored by p24-gag staining by ﬂow
cytometry and by measuring p24-gag in the supernatant by ELISA, as
described (Rapaport et al., 1998; Selliah et al., 2006). In some experi-
ments, NL4-3 virus mutated at NFAT or NFκB proximal binding sites
were used for the infection. Mutations of NFAT or NFκB sites were
performed by PCR site-directed mutagenesis (kit from Stratagene, La
Jolla, CA). Brieﬂy, wild-type HIV-1 LTR sequence (from the Xho I site to
the Nco I site) was ﬁrst subcloned by conventional methods from the
pUC-based vector, pNL4-3 (kindly supplied by Dr. Frederic Bushman,
University of Pennsylvania, Philadelphia, PA), into pMIGR1 (kindly
provided by Dr. Warren Pear, University of Pennsylvania) for mani-
pulationpurposes. PCRprimer pairs containing the proximalHIV-1 LTR
mutant sequences listed below (coding strands only shown)were used
to generate transcription factor binding site variant sequences using
the Site-Directed Mutagenesis Kit. Underlined sequences correspond
to the dual proximal NFAT/NFκB overlapping binding sites, and the
bold/underlined nucleotides are the altered sequences used to disrupt
NFAT and NFκB binding, respectively.
Wild-type: 5′CAAGGGACTTTCCGCTGGGGACTTTCCAGGG3′
NFAT mutant: 5′CAAGGGACTTTGAGCTGGGGACTTTGAAGGG3′
NFκB mutant: 5′CAACTCACTTTCCGCTGCTCACTTTCCAGGG3′
The resultant variant LTR sequences were then subsequently
religated into pNL4-3 prior to transfection into 293T cell lines for
generation ofmutant virions. All mutant sequenceswere conﬁrmed by
DNA sequencing of coding and non-coding strands. Infection of T-cells
was monitored by p24-gag staining by ﬂow cytometry and by
measuring p24-gag in the supernatant by ELISA, as described (Selliah
et al., 2006).
Western blotting and IL-2 detection
FOXP3 or control GFP lentiviral-transduced cells were checked for
protein expression byWestern blotting, as described previously (Selliah
and Finkel, 2001). PVDF membrane was blotted with anti-FOXP3
antibody (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA) or anti-
actin controlmAb (Sigma), and developedwith goat anti-rabbit IgG-HRP
or goat anti-mouse IgG-HRP, respectively, and super signal substrate
(Pierce, Rockford, IL). Optical density of the bands was measured with a
BioRad Quantity One imaging system (BioRad, Hercules, CA).
IL-2 production was evaluated in lentiviral-transduced T-cells by
intracellular staining. FOXP3 or control GFP-transduced T-cells were
activated with PMA (10 ng/ml, Sigma) and ionomycin (1 μM, MP
Biomedicals, Solon, OH) for 6 h without exogenous IL-2. 2 μl of Golgi
STOP (BDBiosciences, San Jose, CA)was added for the ﬁnal 4 h and cells
were ﬁxed in 1% paraformaldehyde (Sigma). T-cells were washed with
PBS and resuspended in 100 μl of PBS containing 0.1% saponin and 10%
FCS. 2.5 μl of anti-human IL-2-APC (BD Biosciences) was added and
incubated at room temperature for 30 min. T-cells were then washed
two times in PBS and analyzed by ﬂow cytometry (FACS Calibur, BD).
Data were analyzed with FlowJo software (Tree Star, Ashland, OR).
Luciferase assays
CD4 T-cells were co-transfected, as described (Cron et al., 2000)
using AMAXA technology (AMAXA® Biosystems, Cologne, Germany),
with pcDNA3 (empty control) or pcDNA3-FOXP3 expression vector,(1.5 μg, a kind gift from Dr. Troy Torgerson, University of Washington,
Seattle, WA) (Lopes et al., 2006), an HIV-1 LTR-ﬁreﬂy luciferase
reporter gene (1 μg) (Cron et al., 2000), and a Renilla luciferase-
expressing transfection control plasmid (pRL-null, 0.5 μg) (Promega,
Madison, WI). HIV-1 LTR-luciferase deletion constructs were gener-
ated as previously described (Chipitsyna et al., 2006). T-cells were
activated with PMA (10 ng/ml) and ionomycin (1 μM) for 6 h and lysed
with passive lysis buffer to measure luciferase activity, as per the
manufacturer's recommendations (Pierce) (Cron et al., 2000). Cell
viability was determined and samples were normalized to equal
numbers of viable cells prior to lysis.
Chromatin immunoprecipitation (ChIP) assays
293T cells were co-transfected, using Fugene 6 reagent (Roche,
Indianapolis, IN), with pcDNA3 (empty control) or pcDNA3-FOXP3
expression vector, along with an NFAT2 expression vector, and an HIV-
1 LTR-luciferase transcriptional reporter plasmid. After 48 h of culture,
cells were harvested and ChIP assay was performed with anti-NFAT2
antibody (Santa Cruz) or anti-FOXP3 antibody (Santa Cruz) or control
Rabbit IgG antibody (Santa Cruz), as described (Selliah et al., 2006),
using the EZ ChIP assay kit (Upstate Biotechnology, Billerica, MA).
Speciﬁcally, cells were cross-linked with 1% formaldehyde, washed,
pelleted, and resuspended in lysis buffer. Each lysate was diluted to
1 ml using Tris/EDTA and sonicated. Sonicates were precleared with
protein G-Sepharose beads and incubated in dilution buffer overnight
at 4 °C with 10 μl of anti-FOXP3, anti-NFAT2, or IgG isotype control
antibodies. Samples were immunoprecipitated with protein G-
Sepharose for 1 h. The beads were washed and eluted, and
supernatants were reverse cross-linked by addition of NaCl and heat
for 6 h at 65 °C. Immunoprecipitated samples were digested with
proteinase K for 1 h at 45 °C, and DNA was extracted with phenol/
chloroform/isoamyl alcohol. The DNAwas then treated with RNase for
30 min at 37 °C, and equal volumes of immunoprecipitated DNAwere
analyzed by real-time PCR. Real-time quantitative PCR was done with
an ABI Prism 7500 Sequence Detection System (PerkinElmer Life
Sciences, Waltham, MA) using PCR primers speciﬁc to the proximal
HIV-1 LTR sequence (Selliah et al., 2006). Fold differences (between
speciﬁc antibody and isotype control antibody) were calculated using
the formula: 2−ΔCt, where ΔCt=Ct(sample)−Ct(control), and Ct
corresponds to the number of ampliﬁcation cycles needed to reach a
speciﬁed threshold value.
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